Overview
- The international Pan Prostate Cancer Group used whole‑genome data from about 1,000 tumours to identify eight reproducible mutational signatures that together explain roughly 85% of prostate cancers.
- Four of those signatures were linked to tumours that are more likely to become metastatic, giving researchers candidate markers to separate low‑risk from high‑risk disease.
- The team found that errors in DNA replication drive about one third of tumours, revealing a common biological process that may open new avenues for treatment research.
- The study was published on Wednesday, September 9, 2026, and authors and funders say the findings must be validated in independent clinical cohorts and converted into tested classifiers before they change patient care.
- If confirmed, the signatures could help target screening to men at higher risk, guide choices between chemotherapy and hormone therapy, and reduce overtreatment by matching care to tumour biology.